LoginSignup
Ocugen logo

Ocugen Stock

StockStock
ISIN: US67577C1053
Ticker: OCGN
US67577C1053
OCGN

Price

Frequently asked questions

What is Ocugen's market capitalization?

The market capitalization of Ocugen is $308.01M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Ocugen?

Ocugen's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.179. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Ocugen's stock?

Currently, 3 analysts cover Ocugen's stock, with a consensus target price of $6.667. Analyst ratings provide insights into the stock's expected performance.

What is Ocugen's revenue over the trailing twelve months?

Over the trailing twelve months, Ocugen reported a revenue of $8.19M.

What is the EBITDA for Ocugen?

Ocugen's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$50.60M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Ocugen?

Ocugen has a free cash flow of -$54.47M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Ocugen's stock?

The 5-year beta for Ocugen is 3.87. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Ocugen have, and what sector and industry does it belong to?

Ocugen employs approximately 65 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Ocugen's shares?

The free float of Ocugen is 283.79M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $308.01M

5Y beta

 3.87

EPS (TTM)

 -$0.179

Free Float

 283.79M

Revenue (TTM)

 $8.19M

EBITDA (TTM)

 -$50.60M

Free Cashflow (TTM)

 -$54.47M

Pricing

1D span
$1.004$1.136
52W span
$0.36$2.105

Analyst Ratings

The price target is $6.667 and the stock is covered by 3 analysts.

Buy

3

Hold

0

Sell

0

Information

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

65

Biotechnology & Drugs

Health Care

Identifier

ISIN

US67577C1053

Primary Ticker

OCGN

Knockouts

Join the conversation
Sign upLogin